

Disclosure of transfers of value made by Spark during 2020 in Ireland

EFPIA template

Date of publication: 30/06/2022

For further information please go to <https://www.sparktx.com/we-are-spark/corporate-social-responsibility-ethics-and-patient-safety/efpia-transparency/> or contact Sunshine@sparktx.com

	Full Name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i> <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>		Euros	TOTAL <i>OPTIONAL</i>
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation		
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
						N/A	N/A						
						N/A	N/A						
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>					N/A	N/A						
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>					N/A	N/A						
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>					N/A	N/A						
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>												
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>												
R & D	AGGREGATE DISCLOSURE												
	Transfers of Value re: Research & Development											135,037.00 €	

latest update: 11 December 2013 v1